2022 World Conference on Lung Cancer (ePosters)-EP02.01-018. EGFR Mutations Promote Lung Adenocarcinoma From Adenocarcinoma in Situ to Minimally Invasive Carcinoma to Invasive Adenocarcinoma

EP02.01-018. EGFR Mutations Promote Lung Adenocarcinoma From Adenocarcinoma in Situ to Minimally Invasive Carcinoma to Invasive Adenocarcinoma

Back to course

Pdf Summary

This study aimed to investigate the differences in gene alterations among three stages of lung adenocarcinoma (adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive adenocarcinoma) and evaluate the impact of EGFR mutations on prognosis. The researchers retrospectively analyzed a database of patients with a single malignant pulmonary nodule and confirmed pN0 stage. Among the 762 cases, 136 were adenocarcinoma in situ, 131 were minimally invasive adenocarcinoma, and 495 were invasive adenocarcinoma. EGFR mutations were identified in 361 patients (47.4%), with a lower mutation rate in adenocarcinoma in situ compared to the other stages. Further analysis showed that EGFR mutations were more prevalent in women, non-smokers, and tumors larger than 2cm. Recurrence and metastasis only occurred in invasive adenocarcinoma cases. For invasive adenocarcinoma patients, those with EGFR mutations had longer disease-free survival and overall survival compared to those without mutations. In conclusion, the frequency of EGFR mutations increases as lung adenocarcinoma progresses from glandular precursor lesions to invasive adenocarcinoma, and EGFR mutation status can serve as a predictor of better prognosis for patients with pT1N0M0 stage.

Asset Subtitle

Jianfei Zhu

Meta Tag

Speaker Jianfei Zhu

Topic Early Stage Non-small Cell Lung Cancer - Biomarkers

Keywords

lung adenocarcinoma

gene alterations

adenocarcinoma in situ

minimally invasive adenocarcinoma

invasive adenocarcinoma

EGFR mutations

prognosis

retrospective analysis

malignant pulmonary nodule

pN0 stage